TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17940861

Group type: EXPERIMENTAL
Intervention: Integrated individual cognitive-behavioral treatment and HIV prevention intervention
Number of subjects: 180

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Both treatment conditions
Number of subjects: 180
Study: 16219571

Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation (SCT)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Autologous SCT
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 222

Group type: COMPARATOR
Intervention: Delayed intensification followed by maintenance chemotherapy
Number of subjects: 222
Study: 12058100

Group type: EXPERIMENTAL
Intervention: Talampanel
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 10604701

Group type: EXPERIMENTAL
Intervention: Laser ablation of the prostate (KTP/neodymium: yttrium‐aluminum‐garnet laser)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 100
Study: 7547040

Group type: EXPERIMENTAL
Intervention: Spinal amethocaine 12 mg in 2 ml of 5% glucose
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Spinal amethocaine 14 mg in 2 ml of 5% glucose
Number of subjects: 40

Group type: COMPARATOR
Intervention: Spinal amethocaine 8 mg in 2 ml of 5% glucose
Number of subjects: 40
Study: 1540304

Group type: EXPERIMENTAL
Intervention: Folinic acid (15 mg bid, po)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 3886712

Group type: EXPERIMENTAL
Intervention: Arildone in vanishing cream
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Arildone in DMSO solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vanishing cream vehicle without arildone
Number of subjects: 0

Group type: COMPARATOR
Intervention: DMSO solution vehicle without arildone
Number of subjects: 0
Study: 30381001

Group type: EXPERIMENTAL
Intervention: POL training (polarized)
Number of subjects: 20

Group type: COMPARATOR
Intervention: THR training (threshold)
Number of subjects: 20
Study: 30053897

Group type: EXPERIMENTAL
Intervention: High flow nasal oxygen therapy (HFNO2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional oxygen therapy (standard low flow oxygen therapy)
Number of subjects: 0
Study: 27026675

Group type: EXPERIMENTAL
Intervention: Trastuzumab (high dose: 8 mg/kg)
Number of subjects: 18111

Group type: EXPERIMENTAL
Intervention: Trastuzumab (low dose: 4 mg/kg)
Number of subjects: 18111

Group type: EXPERIMENTAL
Intervention: Trastuzumab for 1 year
Number of subjects: 18111

Group type: EXPERIMENTAL
Intervention: Trastuzumab for 2 years
Number of subjects: 18111

Group type: EXPERIMENTAL
Intervention: Trastuzumab for 9 weeks
Number of subjects: 18111

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18111
Study: 25350900

Group type: EXPERIMENTAL
Intervention: Expert modeling
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Voice-over PowerPoint
Number of subjects: 20

Group type: COMPARATOR
Intervention: Reading assignments
Number of subjects: 20
Study: 25185361

Group type: EXPERIMENTAL
Intervention: Bufei granule
Number of subjects: 140

Group type: COMPARATOR
Intervention: Bufei placebo
Number of subjects: 140
Study: 21116604

Group type: EXPERIMENTAL
Intervention: GAD‐alum (20 μg subcutaneous injection at baseline and 1 month later)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo (subcutaneous injection at baseline and 1 month later)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: GAD‐alum
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 19181715

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) group
Number of subjects: 110

Group type: COMPARATOR
Intervention: Successful Aging (SA) control group
Number of subjects: 110
Study: 17426112

Group type: EXPERIMENTAL
Intervention: Oil Red O (ORO) staining
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: (1)H‐MR spectroscopy (MRS)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Biochemical assay (BIO)
Number of subjects: 18
Study: 15223098

Group type: EXPERIMENTAL
Intervention: Motivational interviewing intervention (1-hour session)
Number of subjects: 200
Study: 12536654

Group type: EXPERIMENTAL
Intervention: Livial
Number of subjects: 56

Group type: COMPARATOR
Intervention: Oryzanol and Vitamin E
Number of subjects: 56
Study: 9695723

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine 21 mg/24 hr
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine 42 mg/24 hr
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine 63 mg/24 hr
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine (all doses)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine with smoking
Number of subjects: 12
Study: 7626984

Group type: EXPERIMENTAL
Intervention: Combined therapy (erythropoietin + calcitriol)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Erythropoietin monotherapy
Number of subjects: 17
Study: 1720403

Group type: EXPERIMENTAL
Intervention: Intravenous iloprost
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study: 7053590

Group type: EXPERIMENTAL
Intervention: Laser conization
Number of subjects: 110

Group type: COMPARATOR
Intervention: Cold knife conization
Number of subjects: 110
Study: 31996953

Group type: EXPERIMENTAL
Intervention: Interferon beta/interleukin-2 immunotherapy added to first-line salvage hormone therapy (HT)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Historical controls receiving first-line salvage hormone therapy (HT)
Number of subjects: 26
Study: 30296337

Group type: EXPERIMENTAL
Intervention: CARE intervention (psychotherapy delivered via telephone, 5 sessions over 7 weeks)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: CARE intervention
Number of subjects: 59

Group type: COMPARATOR
Intervention: Enhanced Social Work Control arm
Number of subjects: 59
Study: 28964890

Group type: EXPERIMENTAL
Intervention: ABT‐981 (0.3, 1, or 3 mg/kg) every other week for a total of four SC injections
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: ABT‐981 (3 mg/kg) every 4 weeks for a total of three SC injections
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 24491349

Group type: EXPERIMENTAL
Intervention: Automated SMS reminders
Number of subjects: 62

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 62
Study: 23145795

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study: 22674612

Group type: EXPERIMENTAL
Intervention: Gefitinib (250 mg/day)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Pemetrexed (500 mg/m2 on day 1, every 3 weeks)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 135

Group type: COMPARATOR
Intervention: Pemetrexed
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Gefitinib (in patients with EGFR mutation)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Pemetrexed (in patients with EGFR mutation)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Gefitinib (in patients without EGFR mutation)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Pemetrexed (in patients without EGFR mutation)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Gefitinib and Pemetrexed
Number of subjects: 135
Study: 19023279

Group type: EXPERIMENTAL
Intervention: Fenofibrate (160 mg/day)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 17562951

Group type: EXPERIMENTAL
Intervention: Iopamidol
Number of subjects: 414

Group type: COMPARATOR
Intervention: Iodixanol
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Iopamidol (diabetes patients)
Number of subjects: 414

Group type: COMPARATOR
Intervention: Iodixanol (diabetes patients)
Number of subjects: 414
Study: 15064218

Group type: EXPERIMENTAL
Intervention: Physician-administered intervention
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Reinforced counseling (physician + counselor)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Non-intervention
Number of subjects: 113
Study: 11447379

Group type: EXPERIMENTAL
Intervention: Prednisone (30 mg twice daily for 3 days)
Number of subjects: 10
Study: 10410574

Group type: EXPERIMENTAL
Intervention: Chronic renal allograft rejection (Group I)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Stable allograft function (Group II)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Healthy subjects (control)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Chronic renal allograft rejection (Group I) and stable graft function (Group II)
Number of subjects: 34
Study: 8064166

Group type: EXPERIMENTAL
Intervention: Captopril (1 mg/kg, oral)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Remikiren (1 mg/kg, intravenous infusion over 60 min)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (no drug)
Number of subjects: 53
Study: 1932670

Group type: EXPERIMENTAL
Intervention: High-dose terlipressin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Low-dose terlipressin
Number of subjects: 40
Study: 6119724

Group type: EXPERIMENTAL
Intervention: Melperone 10 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Melperone 25 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Melperone 50 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Thioridazine 10 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Thioridazine 25 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Thioridazine 50 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Levomepromazine 10 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Levomepromazine 25 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Levomepromazine 50 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Chlorprotixene 10 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Chlorprotixene 25 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Chlorprotixene 50 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 30719615

Group type: EXPERIMENTAL
Intervention: Olweus Bully Prevention Program (OBPP) combined with a family intervention
Number of subjects: 2859
Study: 29193937

Group type: EXPERIMENTAL
Intervention: Tamsulosin
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Oxybutynin
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Combination of Tamsulosin and Oxybutynin
Number of subjects: 170

Group type: COMPARATOR
Intervention: Control (no treatment mentioned)
Number of subjects: 170
Study: 25549690

Group type: EXPERIMENTAL
Intervention: Computer-based phoneme-discrimination training (twice a week for three weeks)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 27
Study: 24060767

Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 30

Group type: COMPARATOR
Intervention: Glucose solution
Number of subjects: 30
Study: 21875778

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 13776

Group type: COMPARATOR
Intervention: No Clopidogrel
Number of subjects: 13776
Study: 20368852

Group type: EXPERIMENTAL
Intervention: Honey dressing
Number of subjects: 78

Group type: COMPARATOR
Intervention: Silver sulfadiazene (SSD) dressing
Number of subjects: 78
Study: 18261358

Group type: EXPERIMENTAL
Intervention: Group A (yellow ligament dissected, sodium hyaluronate sprinkled)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Group B (yellow ligament reserved)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Group C (yellow ligament reserved, sodium hyaluronate sprinkled)
Number of subjects: 165
Study: 15157690

Group type: EXPERIMENTAL
Intervention: 10 mg.kg(‐1) body weight caffeine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 5 mg.kg(‐1) body weight caffeine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 11307042

Group type: EXPERIMENTAL
Intervention: Ro 41-3696 at 10 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ro 41-3696 at 3 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ro 41-3696 at 5 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ro 41-3696 at 1 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 9494145

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (60 mg daily)
Number of subjects: 2539

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2539
Study: 7805371

Group type: EXPERIMENTAL
Intervention: Gestodene 75 mcg plus ethinyl estradiol 30 mcg
Number of subjects: 176

Group type: COMPARATOR
Intervention: Desogestrel 150 mcg plus ethinyl estradiol 30 mcg
Number of subjects: 176
Study: 3280000

Group type: EXPERIMENTAL
Intervention: Low-dose cyclosporin A (CyA) at a mean dose of 5.5 mg/kg/day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (CyA vehicle)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Low-dose cyclosporin A (CyA) at a mean dose of 5.6 mg/kg/day
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Low-dose cyclosporin A (CyA) at a lower mean dose of 3 mg/kg/day during tapering off phase
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: CyA treatment
Number of subjects: 20
Study: 31813283

Group type: EXPERIMENTAL
Intervention: Holmium Laser Enucleation of Prostate (HoLEP)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Bipolar Plasmakinetic Enucleation of Prostate (BPEP)
Number of subjects: 64
Study: 29159975

Group type: EXPERIMENTAL
Intervention: RCAT (Rhinitis Control Assessment Test)
Number of subjects: 127
Study: 28555959

Group type: EXPERIMENTAL
Intervention: Spironolactone (12.5 mg with eventual escalation to 25 mg daily over a 4-week period)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 0
Study: 25938157

Group type: EXPERIMENTAL
Intervention: Twin-block combined with fixed appliance
Number of subjects: 31

Group type: COMPARATOR
Intervention: Fixed appliance after tooth extraction
Number of subjects: 31

Group type: COMPARATOR
Intervention: Comparison between Twin-block and fixed appliance
Number of subjects: 31
Study: 24455542

Group type: EXPERIMENTAL
Intervention: Arm A (66 Gy in 33 fractions, 5 fractions/week, with concomitant chemotherapy - Cisplatin 30 mg/m² IV once weekly for 6 weeks)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Arm B (66 Gy in 33 fractions, 6 fractions/week)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Arm C (30 Gy in 15 fractions followed by 1.4 Gy twice daily for 15 days, total 72 Gy in 6 weeks)
Number of subjects: 64
Study: 21526444

Group type: EXPERIMENTAL
Intervention: High dose transdermal nicotine (21/14 mg for men/women)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Low dose transdermal nicotine (7 mg)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 104
Study: 18442690

Group type: EXPERIMENTAL
Intervention: OrthoPilot navigation system (B. Braun‐Aesculap, Tuttlingen, Germany)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard manual targeting technique
Number of subjects: 80
Study: 17133529

Group type: EXPERIMENTAL
Intervention: Real tDCS (anode over primary motor cortex)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 32
Study: 12652326

Group type: EXPERIMENTAL
Intervention: Intravenous diltiazem (0.25 mg/kg bolus plus a maintenance infusion)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Intravenous digoxin (13 mcg/kg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intravenous diltiazem
Number of subjects: 24

Group type: COMPARATOR
Intervention: Intravenous digoxin
Number of subjects: 24
Study: 10751074

Group type: EXPERIMENTAL
Intervention: Once-weekly rifapentine + isoniazid (HRp1)
Number of subjects: 762

Group type: EXPERIMENTAL
Intervention: HRp1 given in 2 of every 3 weeks (HRp1.2/3)
Number of subjects: 762

Group type: COMPARATOR
Intervention: Three times weekly isoniazid + rifampicin (HR3)
Number of subjects: 762
Study: 8609830

Group type: EXPERIMENTAL
Intervention: Adjuvant recombinant human growth hormone (rhGH) treatment (0.15 mg/kg/d)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vehicle of infusion (Control)
Number of subjects: 20
Study: 1575820

Group type: EXPERIMENTAL
Intervention: bezafibrate 600 mg/day
Number of subjects: 83

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 83
Study: 4048364

Group type: EXPERIMENTAL
Intervention: Cardiovascular conditioning program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control program (designed to give the appearance of physical training)
Number of subjects: 0
Study: 30368981

Group type: EXPERIMENTAL
Intervention: Droperidol
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 215

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215
Study: 30232699

Group type: EXPERIMENTAL
Intervention: Bisoprolol-Amlodipine 5 mg/5 mg Combination Tablet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bisoprolol 5 mg Tablet and Amlodipine 5 mg Tablet (Control)
Number of subjects: 0
Study: 27634471

Group type: EXPERIMENTAL
Intervention: Robot Gym therapy (technology-assisted rehabilitation)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 20
Study: 24658389

Group type: EXPERIMENTAL
Intervention: Adoption of three/four healthy behaviors
Number of subjects: 867

Group type: COMPARATOR
Intervention: No change in health behaviors
Number of subjects: 867
Study: 22308241

Group type: EXPERIMENTAL
Intervention: COGRAT (Cognitive therapy + Graded activity training)
Number of subjects: 83

Group type: COMPARATOR
Intervention: CO (Cognitive therapy only)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: COGRAT
Number of subjects: 83

Group type: COMPARATOR
Intervention: CO
Number of subjects: 83
Study: 20736151

Group type: EXPERIMENTAL
Intervention: Maraviroc + Optimized Background Therapy (OBT)
Number of subjects: 635

Group type: COMPARATOR
Intervention: Placebo + Optimized Background Therapy (OBT)
Number of subjects: 635
Study: 17585116

Group type: EXPERIMENTAL
Intervention: Erythromycin 2 days + midazolam (2.5 mg) (EM2)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Erythromycin 4 days + midazolam (2.5 mg) (EM4)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Erythromycin 7 days + midazolam (2.5 mg) (EM7)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Midazolam (5 mg) without erythromycin (EM0)
Number of subjects: 12
Study: 15693914

Group type: EXPERIMENTAL
Intervention: Lactobacillus GG (LGG)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Mixture of four probiotic strains (MIX)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230
Study: 12227708

Group type: EXPERIMENTAL
Intervention: Bezafibrate (400 mg/day) for 6 months
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no bezafibrate)
Number of subjects: 24
Study: 10509849

Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg once daily for nonulcer patients, 20 mg twice daily for ulcer patients for 14 days) plus two antimicrobials (amoxicillin, clarithromycin or roxithromycin, metronidazole, ornidazole, or tinidazole for 10 days)
Number of subjects: 518
Study: 7760866

Group type: EXPERIMENTAL
Intervention: Six weeks of oral anticoagulant therapy (warfarin or dicumarol)
Number of subjects: 902

Group type: COMPARATOR
Intervention: Six months of oral anticoagulant therapy (warfarin or dicumarol)
Number of subjects: 902
Study: 2179082

Group type: EXPERIMENTAL
Intervention: D,L-Kavain (Neuronika)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Oxazepam
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 6780632

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment
Number of subjects: 52
Study: 31219504

Group type: EXPERIMENTAL
Intervention: Active deep brain stimulation
Number of subjects: 11

Group type: COMPARATOR
Intervention: Deep brain stimulation switched off
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Active deep brain stimulation during movement task
Number of subjects: 11
Study: 27933512

Group type: EXPERIMENTAL
Intervention: Chinese medicine treatment (Zuogui Pill and Yougui Pill for low risk; Qingwen Baidu Decoction and Bazhen Decoction for moderate risk; Gexia Zhuyu Decoction and Qinghao Biejia Decoction combined with Shiquan Dabu Decoction for high risk)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional therapy (control group)
Number of subjects: 60
Study: 26015773

Group type: EXPERIMENTAL
Intervention: Brief weight reduction intervention during routine consultations
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 50
Study: 22944725

Group type: EXPERIMENTAL
Intervention: Positive P. aeruginosa serology (baseline)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Seropositivity to alkaline protease
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Seropositivity to exotoxin A
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline seropositivity
Number of subjects: 0
Study: 21067823

Group type: EXPERIMENTAL
Intervention: Topical lidocaine hydrochloride (20 mg/ml) with 0.00125% epinephrine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Topical 0.5% bupivacaine hydrochloride
Number of subjects: 60

Group type: COMPARATOR
Intervention: Topical saline
Number of subjects: 60
Study: 19846734

Group type: EXPERIMENTAL
Intervention: naltrexone/bupropion (NB16)
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: naltrexone/bupropion (NB32)
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: naltrexone/bupropion (NB48)
Number of subjects: 419
Study: 18154996

Group type: EXPERIMENTAL
Intervention: Surgical revascularization
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: Endovascular revascularization
Number of subjects: 376

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 376
Study: 15459217

Group type: EXPERIMENTAL
Intervention: R115777 (300 mg twice daily)
Number of subjects: 368

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 368
Study: 14510128

Group type: EXPERIMENTAL
Intervention: Routine nursing care plus interrupted direct current (IDC) stimulations
Number of subjects: 7

Group type: COMPARATOR
Intervention: Routine nursing care plus placebo IDC
Number of subjects: 7